Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis - PubMed
2 days ago
- #Inhaled Treprostinil
- #Idiopathic Pulmonary Fibrosis
- #Clinical Trial
- Inhaled treprostinil shows potential for treating idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism.
- A phase 3, double-blind trial involving 593 IPF patients compared inhaled treprostinil (298 patients) with placebo (295 patients) over 52 weeks.
- Primary endpoint: Change in absolute forced vital capacity (FVC) at week 52 showed a smaller decline in the treprostinil group (-49.9 ml) vs. placebo (-136.4 ml), with a significant between-group difference (95.6 ml, P<0.001).
- Secondary endpoints: Clinical worsening occurred less in the treprostinil group (27.2%) vs. placebo (39.0%), hazard ratio 0.71 (P=0.02). No significant difference in IPF exacerbation time.
- Safety: Common adverse event was cough (48.3% treprostinil vs. 24.1% placebo). Discontinuation rates were 33.6% (treprostinil) and 24.7% (placebo), with adverse events cited in half of cases.
- Conclusion: Inhaled treprostinil was associated with a smaller FVC decline and fewer clinical-worsening events in IPF patients over 52 weeks.